Skip to main content

Table 2 Association of Epidermal growth factor receptor (EGFR) expression with clinico-pathologic parameters of Endometrial carcinoma

From: Epidermal growth factor receptor (EGFR) overexpression in endometrial carcinoma: association with histopathologic parameters

   n(%) P-Value
Negative (n=65) Low (n=19) High (n=5)
Menopausal Status Pre Menopausal 13 (20) 4 (21.1) 0 (0) 0.792
Post Menopausal 52 (80) 15 (78.9) 5 (100)
Histological Type endometroid 60 (92.3) 14 (73.7) 3 (60) 0.009
serous 3 (4.6) 4 (21.1) 0 (0)
clear cell 1 (1.5) 0 (0) 0 (0)
carcinosarcoma 1 (1.5) 1 (5.3) 2 (40)
Grade Grade I 28 (43.1) 6 (31.6) 1 (20) 0.055
Grade II 30 (46.2) 6 (31.6) 2 (40)
Grade III 7 (10.8) 7 (36.8) 2 (40)
Myometial Invasion Limited To Endometrium 6 (9.2) 0 (0) 0 (0) 0.753
<1/2 Of Myometrium 23 (35.4) 6 (31.6) 2 (40)
>1/2 Of Myometrium 36 (55.4) 13 (68.4) 3 (60)
Cervical Invasion Present 15 (23.1) 6 (31.6) 2 (40) 0.524
Absent 50 (76.9) 13 (68.4) 3 (60)
Nodal Status N0 61 (93.8) 18 (94.7) 5 (100) 1.000
N1 3 (4.6) 1 (5.3) 0 (0)
N2 1 (1.5) 0 (0) 0 (0)
Lymphovascular Invasion Present 3 (4.6) 3 (15.8) 0 (0) 0.278
Absent 62 (95.4) 16 (84.2) 5 (100)
T Stage T1 47 (72.3) 13 (68.4) 62 (69.7) 0.094
T2 12 (18.5) 2 (10.5) 16 (18)
T3 4 (6.2) 4 (21.1) 8 (9)
T4 2 (3.1) 0 (0) 3 (3.4)
FIGO Stage Stage IA 26 (40) 6 (31.6) 2 (40) 0.155
Stage IB 20 (30.8) 7 (36.8) 0 (0)
Stage II 13 (20) 2 (10.5) 2 (40)
Stage IIIA 4 (6.2) 3 (15.8) 0 (0)
Stage IIIB 0 (0) 1 (5.3) 0 (0)
Stage IV 2 (3.1) 0 (0) 1 (20)
Adnexal involvement Present 5 (7.7) 3 (15.8) 1 (20) 0.321
Absent 60 (92.3) 16 (84.2) 4 (80)
  1. Fisher exact test applied
  2. P-value ≤ 0.05, considered as significant